Your browser doesn't support javascript.
loading
Microbes mediated immunogenic cell death in cancer immunotherapy.
Huang, Jumin; Duan, Fugang; Xie, Chun; Xu, Jiahui; Zhang, Yizhong; Wang, Yuwei; Tang, Yu-Ping; Leung, Elaine Lai-Han.
Afiliação
  • Huang J; Cancer Center, Faculty of Health Sciences, University of Macau, Macau (SAR), China.
  • Duan F; MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China.
  • Xie C; Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Xu J; NHC Key Laboratory of Medical Immunology, Peking University Health Science Center, Beijing, China.
  • Zhang Y; Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China.
  • Wang Y; Cancer Center, Faculty of Health Sciences, University of Macau, Macau (SAR), China.
  • Tang YP; MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China.
  • Leung EL; Cancer Center, Faculty of Health Sciences, University of Macau, Macau (SAR), China.
Immunol Rev ; 321(1): 128-142, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37553793
ABSTRACT
Immunogenic cell death (ICD) is one of the 12 distinct cell death forms, which can trigger immune system to fight against cancer cells. During ICD, a number of cellular changes occur that can stimulate an immune response, including the release of molecules called damage-associated molecular patterns (DAMPs), signaling to immune cells to recognize and attack cancer cells. By virtue of their pivotal role in immune surveillance, ICD-based drug development has been a new approach to explore novel therapeutic combinations and personalized strategies in cancer therapy. Several small molecules and microbes can induce ICD-relevant signals and cause cancer cell death. In this review, we highlighted the role of microbe-mediate ICD in cancer immunotherapy and described the mechanisms through which microbes might serve as ICD inducers in cancer treatment. We also discussed current attempts to combine microbes with chemotherapy regimens or immune checkpoint inhibitors (ICIs) in the treatment of cancer patients. We surmise that manipulation of microbes may guide personalized therapeutic interventions to facilitate anticancer immune response.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Immunol Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Immunol Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China